Have a Good Trip Benefit Show to Celebrate MAPS and Psychedelic Medicine
The Flaming Lips, Eric Andre, and Reggie Watts to headline benefit show on Thursday, June 22, at the Mission Ballroom...
Clinical Trial
PDS Biotech Completes Enrollment in Immune Checkpoint Inhibitor Naïve Arm of VERSATILE-002 Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck Cancer
Company plans to initiate VERSATILE-003 Phase 3 clinical trial in late 2023FLORHAM PARK, N.J., May 18, 2023 (GLOBE NEWSWIRE) --...
Galera Announces FDA Orphan Drug Designation Granted to Rucosopasem for Pancreatic Cancer
Rucosopasem in clinical development to augment the anti-cancer efficacy of stereotactic body radiation therapyMALVERN, Pa., May 18, 2023 (GLOBE NEWSWIRE)...
Replimune Reports Fiscal Fourth Quarter and Year Ended 2023 Financial Results and Provides Corporate Update
Topline data disclosure from the registration-directed CERPASS clinical trial of RP1 combined with Libtayo® (cemiplimab-rwlc) in cutaneous squamous cell carcinoma...
Science 37 Wins 2023 MedTech Breakthrough Award for “Best Overall Clinical Trial Platform”
Science 37's unified platform that powers the Metasite receives award for outstanding digital health and technology innovationRESEARCH TRIANGLE PARK, N.C., May...
Cognition Therapeutics Publishes Clinical Evidence that CT1812 Displaces Aβ Oligomers from Binding to Neuronal Synapses in Alzheimer’s Disease
- First Human Evidence that CT1812 Selectively Engages Aβ OligomersPURCHASE, N.Y., May 18, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc....
FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia
Met primary endpoint of noninferiority of roxadustat to erythropoietin alfaPlan to file supplemental New Drug Application in ChinaSAN FRANCISCO and...
Orchard Therapeutics Presents Data from Research Programs at ASGCT Demonstrating the Ability of HSC Gene Therapy to Address Larger Indications
Preclinical proof-of-concept data show the therapeutic potential of OTL-104 for NOD2 Crohn’s disease, a severe and treatment-refractory form of the...
Kymera Therapeutics Presents Clinical Data from the Phase 1 Trial of IRAK4 Degrader, KT-474 (SAR444656), at the European Academy of Dermatology and Venereology Symposium
In the Phase 1 trial, KT-474 showed evidence of robust IRAK4 degradation in blood and skin lesions as well as...
EyePoint Pharmaceuticals Announces Sale of YUTIQ® to Alimera Sciences, Inc. for $82.5 Million Cash Plus Royalties
–$75M paid at closing with an additional $7.5M payable in equal quarterly installments in 2024 – All outstanding bank debt...
PepGen Announces Clearance by Health Canada of CTA for PGN-EDO51 to Begin the Phase 2 Clinical Trial, CONNECT1-EDO51, for the Treatment of Duchenne Muscular Dystrophy
- CONNECT1-EDO51 will assess dystrophin levels, exon skipping data and safety data following multiple doses of PGN-EDO51 in patients with...
ASLAN Pharmaceuticals Doses First Patient in Phase 2a Trial of Farudodstat in Alopecia Areata
The Phase 2a, proof-of-concept study, called FAST-AA (FArudodstat STudy in Alopecia Areata), will enroll approximately 60 adult patients in the...
Prelude Therapeutics Announces Pricing of Public Offering
WILMINGTON, Del., May 18, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated ("Prelude" or the "Company") (Nasdaq: PRLD), a clinical-stage precision...
Voyager Therapeutics Presents Robust, Multi-Species Results from Preclinical Studies of IV-Delivered, TRACER™-Generated Novel Capsids at the ASGCT 26th Annual Meeting
Oral presentation features further evaluation of second-generation capsids, demonstrating increased transduction in several brain areas across multiple non-human primate speciesCAMBRIDGE,...
Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 18, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN),...
Cabaletta Bio Announces Pricing of Public Offering of Common Stock
PHILADELPHIA, May 17, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company...
Corvus Pharmaceuticals to Present New CPI-818 Data at the International Conference on Malignant Lymphoma
BURLINGAME, Calif., May 17, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that...
Umoja Biopharma Presents New Preclinical Data at the American Society of Gene and Cell Therapy 26th Annual Meeting Demonstrating Potent In Vivo CAR T Cell Generation and Durable Anti-Tumor Activity
UB-VV200 preclinical data highlight successful generation of TagCAR T cells, which demonstrate dose-dependent anti-tumor activity when used in combination with...
NeuroOne® Announces First Clinical Case Using Evo® sEEG Electrode in Robotic Neurosurgery
Evo sEEG electrode used with Zimmer Biomet’s ROSA One® Brain during procedure at Cleveland Clinic EDEN PRAIRIE, Minn., May 17,...
Brain Cancer Canada Matches Community Fundraising to Support Groundbreaking DIPG Research
TORONTO, May 17, 2023 (GLOBE NEWSWIRE) -- Brain Cancer Canada (BCC), a leading advocate in the fight against brain cancers,...